Generic placeholder image

Endocrine, Metabolic & Immune Disorders - Drug Targets

Author(s): Josep Darbà* and Alicia Marsà

DOI: 10.2174/1871530319666190807162344

DownloadDownload PDF Flyer Cite As
Current Status and Use of Resources of Lysosomal Storage Diseases: Analysis of a Spanish Claims Database

Page: [263 - 270] Pages: 8

  • * (Excluding Mailing and Handling)

Abstract

Background: The knowledge of the pathophysiology of Lysosomal Storage Disorders has gradually increased, but information on their incidence is still scarce. The objective of this study was to evaluate the status and use of resources of these disorders in Spain from 1997 to 2015.

Methods: Records from 4,999 patients diagnosed with a Lysosomal Storage Disorder were extracted from a Spanish database containing data from public and private hospitals from 1997 to 2015.

Results: The database registered 2,441 patients with an LSD in Spain during the study period. Leukodystrophy, Krabbe disease, Pelizaeus-Merzbacher disease and sulfatide lipidosis represented, as a group, the most common combination of diseases in Spain, affecting 26% of total patients. The average age of diagnosis of these disorders was 16.7 years. A sex bias was observed in most of the groups, with a proportion of male/female of 60 to 40%. The direct medical cost of Lysosomal Storage Diseases was €5,686 per patient with an average cost per hospital admission of €4,923. Global costs displayed a growing tendency.

Conclusion: Contrary to worldwide disease incidence estimations, the group with Krabbe disease registered the highest number of patients in the study period, which makes evident the need for accurate regional disease incidence and patient demographic studies. Altogether, data suggest the need to improve LSDs diagnostic protocols, and support the inclusion of these disorders in standard newborn screening programs.

Keywords: Lysosomal storage diseases, inherited metabolic diseases, claims database analysis, economic impact study, Spain, Krabbe disease.

Graphical Abstract

[1]
Platt, F.M.; d’Azzo, A.; Davidson, B.L.; Neufeld, E.F.; Tifft, C.J. Lysosomal storage diseases. Nat. Rev. Dis. Primers, 2018, 4(1), 27.
[http://dx.doi.org/10.1038/s41572-018-0025-4]] [PMID: 30275469]
[2]
Boustany, R.M. Lysosomal storage diseases--the horizon expands. Nat. Rev. Neurol., 2013, 9(10), 583-598.
[http://dx.doi.org/10.1038/nrneurol.2013.163]] [PMID: 23938739]
[3]
Gaucher, P.C.E. De l’épithélioma primitive de la rate; Thése de Paris, 1882.
[4]
Anderson, W. A case of “angeiokeratoma”. Br. J. Dermatol., 1898, 10, 113-117.
[http://dx.doi.org/10.1111/j.1365-2133.1898.tb16317.x]]
[5]
Fabry, J. Ein Beitrag zurt Kenntnis der Purpura haemorrhagica nodularis (Purpura papulosa haemorrhagica Hebrae). Arch. Dermatol. Syph., 1898, 43, 187-200.
[http://dx.doi.org/10.1007/BF01986897]]
[6]
Duve, C. Exploring cells with a centrifuge. Science, 1975, 189(4198), 186-194.
[http://dx.doi.org/10.1126/science.1138375]] [PMID: 1138375]
[7]
Li, M. Enzyme replacement therapy: A review and its role in treating Lysosomal storage diseases. Pediatr. Ann., 2018, 47(5), e191-e197.
[http://dx.doi.org/10.3928/19382359-20180424-01]] [PMID: 29750286]
[8]
US National Library of Medicine, Genetics Home Reference. NIH. 2019. https://ghr.nlm.nih.gov/ [Accessed February 12, 2019];
[9]
Burlina, A.B.; Polo, G.; Salviati, L.; Duro, G.; Zizzo, C.; Dardis, A.; Bembi, B.; Cazzorla, C.; Rubert, L.; Zordan, R.; Desnick, R.J.; Burlina, A.P. Newborn screening for lysosomal storage disorders by tandem mass spectrometry in North East Italy. J. Inherit. Metab. Dis., 2018, 41(2), 209-219.
[http://dx.doi.org/10.1007/s10545-017-0098-3] [PMID: 29143201]
[10]
Burton, B.K.; Charrow, J.; Hoganson, G.E.; Waggoner, D.; Tinkle, B.; Braddock, S.R.; Schneider, M.; Grange, D.K.; Nash, C.; Shryock, H.; Barnett, R.; Shao, R.; Basheeruddin, K.; Dizikes, G. Newborn Screening for Lysosomal Storage Disorders in Illinois: The Initial 15-Month Experience. J. Pediatr., 2017, 190, 130-135.
[http://dx.doi.org/10.1016/j.jpeds.2017.06.048]] [PMID: 28728811]
[11]
Registro de Altas de los Hospitales Generales del Sistema Nacional de Salud. Conjunto Mínimo de Bases de Datos (CMBD). https://www.mscbs.gob.es/estadEstudios/estadisticas/cmbdAnteriores.htm [Accessed October 10, 2018];
[12]
Colon, C.; Ortolano, S.; Melcon-Crespo, C.; Alvarez, J.V.; Lopez-Suarez, O.E.; Couce, M.L.; Fernández-Lorenzo, J.R. Newborn screening for Fabry disease in the north-west of Spain. Eur. J. Pediatr., 2017, 176(8), 1075-1081.
[http://dx.doi.org/10.1007/s00431-017-2950-8] [PMID: 28646478]
[13]
Orphanet, The portal for rare diseases and orphan drugs. Retrieved from:. https://www.orpha.net/consor/cgi-bin/index.php?lng=EN [Accessed February, 2019];
[14]
Ausems, M.G.; Verbiest, J.; Hermans, M.P.; Kroos, M.A.; Beemer, F.A.; Wokke, J.H.; Sandkuijl, L.A.; Reuser, A.J.; van der Ploeg, A.T. Frequency of glycogen storage disease type II in The Netherlands: implications for diagnosis and genetic counselling. Eur. J. Hum. Genet., 1999, 7(6), 713-716.
[http://dx.doi.org/10.1038/sj.ejhg.5200367]] [PMID: 10482961]
[15]
Mistry, P.K.; Sadan, S.; Yang, R.; Yee, J.; Yang, M. Consequences of diagnostic delays in type 1 Gaucher disease: the need for greater awareness among hematologists-oncologists and an opportunity for early diagnosis and intervention. Am. J. Hematol., 2007, 82(8), 697-701.
[http://dx.doi.org/10.1002/ajh.20908]] [PMID: 17492645]
[16]
Fernandes Filho, J.A.; Shapiro, B.E. Tay-Sachs disease. Arch. Neurol., 2004, 61(9), 1466-1468.
[http://dx.doi.org/10.1001/archneur.61.9.1466]] [PMID: 15364698]
[17]
Muenzer, J. The mucopolysaccharidoses: a heterogeneous group of disorders with variable pediatric presentations. J. Pediatr., 2004, 144(5)(Suppl.), S27-S34.
[http://dx.doi.org/10.1016/j.jpeds.2004.01.052]] [PMID: 15126981]
[18]
Brunetti-Pierri, N.; Scaglia, F. GM1 gangliosidosis: review of clinical, molecular, and therapeutic aspects. Mol. Genet. Metab., 2008, 94(4), 391-396.
[http://dx.doi.org/10.1016/j.ymgme.2008.04.012]] [PMID: 18524657]
[19]
Graziano, A.C.; Cardile, V. History, genetic, and recent advances on Krabbe disease. Gene, 2015, 555(1), 2-13.
[http://dx.doi.org/10.1016/j.gene.2014.09.046]] [PMID: 25260228]
[20]
van Rappard, D.F.; Boelens, J.J.; Wolf, N.I. Metachromatic leukodystrophy: Disease spectrum and approaches for treatment. Best Pract. Res. Clin. Endocrinol. Metab., 2015, 29(2), 261-273.
[http://dx.doi.org/10.1016/j.beem.2014.10.001]] [PMID: 25987178]
[21]
Kleinert, J.; Dehout, F.; Schwarting, A.; de Lorenzo, A.G.; Ricci, R.; Kampmann, C.; Beck, M.; Ramaswami, U.; Linhart, A.; Gal, A.; Houge, G.; Widmer, U.; Mehta, A.; Sunder-Plassmann, G. Prevalence of uncontrolled hypertension in patients with Fabry disease. Am. J. Hypertens., 2006, 19(8), 782-787.
[http://dx.doi.org/10.1016/j.amjhyper.2006.01.011]] [PMID: 16876675]
[22]
Linhart, A.; Elliott, P.M. The heart in Anderson-Fabry disease and other lysosomal storage disorders. Heart, 2007, 93(4), 528-535.
[http://dx.doi.org/10.1136/hrt.2005.063818]] [PMID: 17401074]
[23]
Harambat, J.; van Stralen, K.J.; Espinosa, L.; Groothoff, J.W.; Hulton, S.A.; Cerkauskiene, R.; Schaefer, F.; Verrina, E.; Jager, K.J.; Cochat, P. Characteristics and outcomes of children with primary oxalosis requiring renal replacement therapy. Clin. J. Am. Soc. Nephrol., 2012, 7(3), 458-465.
[http://dx.doi.org/10.2215/CJN.07430711]] [PMID: 22223608]
[24]
van der Hoeven, S.M.; van Woerden, C.S.; Groothoff, J.W. Primary hyperoxaluria type 1, a too often missed diagnosis and potentially treatable cause of end-stage renal disease in adults: results of the Dutch cohort. Nephrol. Dial. Transplant., 2012, 27(10), 3855-3862.
[http://dx.doi.org/10.1093/ndt/gfs320]] [PMID: 22844106]
[25]
Calderón Sandubete, E. Briones Pérez de la Blanca, E.; Alonso Ortiz del Río, C.; Marín León, I., Eds.; en nombre del Grupo de Trabajo para la Guía. Guía de práctica clínica multidisciplinar española sobre enfermedad de Anderson-Fabry, Ed. Enebro: Sevilla. 2018.
[26]
Sun, A. Lysosomal storage disease overview. Ann. Transl. Med., 2018, 6(24), 476.
[http://dx.doi.org/10.21037/atm.2018.11.39]] [PMID: 30740407]
[27]
Lorenzo, V.; Torres, A.; Salido, E. Primary hyperoxaluria. Nefrologia, 2014, 34(3), 398-412.
[PMID: 24798559]
[28]
Wyatt, K.; Henley, W.; Anderson, L.; Anderson, R.; Nikolaou, V.; Stein, K.; Klinger, L.; Hughes, D.; Waldek, S.; Lachmann, R.; Mehta, A.; Vellodi, A.; Logan, S. The effectiveness and cost-effectiveness of enzyme and substrate replacement therapies: a longitudinal cohort study of people with lysosomal storage disorders. Health Technol. Assess., 2012, 16(39), 1-543.
[http://dx.doi.org/10.3310/hta16390]] [PMID: 23089251]
[29]
Beutler, E. Lysosomal storage diseases: natural history and ethical and economic aspects. Mol. Genet. Metab., 2006, 88(3), 208-215.
[http://dx.doi.org/10.1016/j.ymgme.2006.01.010]] [PMID: 16515872]
[30]
Extended neonatal screening for Lysosomal diseases by mass spectrometry. Executive summary. Informes de evaluación de tecnologías sanitarias, AETSA 2011/11. Consejería de Salud, Junta de Andalucía.
[31]
Marín Soria, J.L.; Aldamiz-Echevarría, L.; Castiñeiras Ramos, D.E.; Dalmau Serra, J.; Fernández Sánchez, A.; González Lamuño, D.; Juan Fita, M.; Jiménez Jiménez, L.M.; Fernández Sánchez, A. Programas de cribado neonatal en España: Actualización y propuestas de futuro. Documento de consenso. Ministerio de Sanidad, Gobierno de España. 2010.